Indapamide, a Thiazide-Like Diuretic, Decreases Bone Resorption In Vitro

Lalande, Alain; Roux, Sophie; Denne, M A; Stanley, E. Richard; Schiavi, Pierre; Guez, David; Vernejoul, M. C. De

doi:10.1359/jbmr.2001.16.2.361

Cited by 33 publications

(26 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The exact role of thiazides on bone cell is still under debate [51]. Some studies indicate that thiazides are capable of reducing osteoclastic activity [52,53]. Moreover, it has been suggested that thiazides directly stimulate osteoblast differentiation and bone mineral formation, independent of their effects in the kidney [54,55].…”

Section: Discussionmentioning

confidence: 99%

Effect of thiazides on bone mineral density in children with idiopathic hypercalciuria

et al. 2011

View full text Add to dashboard Cite

To determine the effect of thiazide treatment on bone mineral density (BMD) in children with idiopathic hypercalciuria (IH) and osteopenia, we reviewed the case notes of 22 children aged 11.7 ± 2.7 years diagnosed with IH and osteopenia who had received thiazides for 2.4 years. The data on this group were compared with those of 32 IH children with osteopenia aged 11.2 ± 2.7 years who had not received thiazide treatment. By the end of the follow-up period, the z-BMD had improved spontaneously in 23 of the 32 control children (72%) and in 12 of the 22 patients on thiazides (54%). Although treated patients had a higher body mass index (BMI) and a higher BMD following treatment, the differences became statistically negligible when these parameters were expressed as z-BMD or as bone mineral apparent density (BMAD). In contrast, within the control group, there were significant differences in BMAD and z-BMD at the end of the follow-up. Patients who had an improved z-BMD at the end of the treatment also showed an increase in their BMI. Based on these results, we conclude that thiazide treatment does not improve the z-BMD in children with IH. More than half of the children suffering from IH enrolled in our study showed a spontaneous improvement in their z-BMD, which was more evident when the initial BMAD was not low and when their BMI increased during the follow-up period.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of thiazides on bone mineral density in children with idiopathic hypercalciuria

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In vitro , thiazides have a selective effect on human osteoblast-like cell lines, directly stimulating osteocalcin production in human osteoblasts and increasing the expression of thiazide-sensitive sodium chloride cotransporter in osteoblast-like cells, which is the target of thiazide diuretics 141–143. The mitogenic action of thiazide and the thiazide-related diuretic, indapamide, has been shown to be in part due to increased osteoblastic cell proliferation 144,145. This in vitro effect was also associated with inhibition of osteoclastic bone resorption as a result of the reduction of osteoclastic cell differentiation mediated through direct inhibition of hematopoietic precursors 144,146,147.…”

Section: Potential Therapeutic Regimensmentioning

confidence: 99%

Nephrolithiasis-associated bone disease: pathogenesis and treatment options

Sakhaee

Maalouf

Kumar

et al. 2011

Kidney International

144

View full text Add to dashboard Cite

Nephrolithiasis remains a formidable health problem in the United States and worldwide. A very important but underaddressed area in nephrolithiasis is the accompanying bone disease. Epidemiologic studies have shown that osteoporotic fractures occur more frequently in patients with nephrolithiasis than in the general population. Decreased bone mineral density and defects in bone remodeling are commonly encountered in patients with calcium nephrolithiasis. The pathophysiologic connection of bone defects to kidney stones is unknown. Hypercalciuria and hypocitraturia are two important risk factors for stone disease, and treatments with thiazide diuretics and alkali, respectively, have been shown to be useful in preventing stone recurrence in small prospective trials. However, no studies have examined the efficacy of these agents or other therapies in preventing continued bone loss in calcium stone formers. This manuscript reviews the epidemiology, pathophysiology, and potential treatments of bone disease in patients with nephrolithiasis.

show abstract

“…Bisphosphonates also reduce urinary calcium excretion in normal and hypercalciuric patients (187, 188 ). Thiazides act by stimulating calcium reabsorption in the distal convoluted tubule and also stimulate osteoblast differentiation with a reduction in stone recurrence rate, osteoporotic fractures and an increase in BMD (187, 189–196) .…”

Section: Introductionmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management

Mirza

Canalis

2015

European Journal of Endocrinology

259

164

View full text Add to dashboard Cite

Osteoporosis is a skeletal disorder characterized by decreased bone mineral density and compromised bone strength predisposing to an increased risk of fractures. Although idiopathic osteoporosis is the most common form of osteoporosis, secondary factors may contribute to the bone loss and increased fracture risk in patients presenting with fragility fractures or osteoporosis. Several medical conditions and medications significantly increase the risk for bone loss and skeletal fragility. This review focuses on some of the common causes of osteoporosis, addressing the underlying mechanisms, diagnostic approach and treatment of low bone mass in the presence of these conditions.

show abstract

Indapamide, a Thiazide-Like Diuretic, Decreases Bone Resorption In Vitro

Cited by 33 publications

References 50 publications

Effect of thiazides on bone mineral density in children with idiopathic hypercalciuria

Effect of thiazides on bone mineral density in children with idiopathic hypercalciuria

Nephrolithiasis-associated bone disease: pathogenesis and treatment options

MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management

Contact Info

Product

Resources

About